Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Passage BIO, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 110
- +8 vs. Q4 2021
- Shares held
- 43.0M
- −761.7K (−1.7%) vs. Q4 2021
- Total value
- $133.2M
- −$144.5M (−52.0%) vs. Q4 2021
- New holders
- 24
- 34 more added
- Sold out
- 16
- 30 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PASG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 29 | $6.82M |
| Q1 2026 | 35 | $13.8M |
| Q4 2025 | 30 | $18.6M |
| Q3 2025 | 32 | $13.2M |
| Q2 2025 | 41 | $13.0M |
| Q1 2025 | 42 | $12.8M |
| Q4 2024 | 46 | $21.6M |
| Q3 2024 | 45 | $27.1M |
| Q2 2024 | 45 | $32.0M |
| Q1 2024 | 51 | $54.4M |
| Q4 2023 | 52 | $33.1M |
| Q3 2023 | 51 | $21.3M |
| Q2 2023 | 56 | $31.4M |
| Q1 2023 | 59 | $34.0M |
| Q4 2022 | 68 | $51.6M |
| Q3 2022 | 76 | $49.3M |
| Q2 2022 | 87 | $99.6M |
| Q1 2022 | 110 | $133.2M |
| Q4 2021 | 102 | $277.7M |
| Q3 2021 | 103 | $419.1M |
| Q2 2021 | 102 | $558.8M |
| Q1 2021 | 90 | $786.5M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Passage BIO, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 1,020,800 | $3.16M | 0.06% | +485,800+90.8% | Added |
| Highline Capital Management, L.P. | 1,235,869 | $3.83M | 4.65% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,734,894 | $5.38M | 0.00% | −180,192−9.4% | Reduced |
| Woodline Partners LP | 1,913,880 | $5.93M | 0.10% | −1,143−0.1% | Reduced |
| New Leaf Venture Partners, L.L.C. | 2,497,922 | $7.74M | 3.82% | 00.0% | Unchanged |
| BlackRock Inc. | 3,292,792 | $10.2M | 0.00% | −198,763−5.7% | Reduced |
| Deep Track Capital, LP | 3,375,000 | $10.5M | 0.68% | +158,003+4.9% | Added |
| Versant Venture Management, LLC | 4,959,769 | $15.4M | 15.35% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 5,009,219 | $15.5M | 1.32% | +5,009,219 | New |
| OrbiMed Advisors LLC | 7,331,999 | $22.7M | 0.37% | +369,100+5.3% | Added |
| Frazier Management LLC | 0 | $0 | 0.00% | −5,009,219−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −90,787−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −57,381−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −50,170−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −26,595−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −21,524−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −18,653−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −15,481−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −14,570−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −10,730−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −3,294−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −1,241−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −395−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Koshinski Asset Management, Inc. | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −6−100.0% | Sold out |